← 홈

폐암 (NSCLC) · EGFR

11개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 11개
CGTBiologicstaleGuangzhou Bio-gene Technology C…Phase 1

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

Non Small Cell Lung Cancer · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
AntibodystaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 ACTIVE
ADCBiologicstaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 64.6%임상시험 1상태 ACTIVE
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 42.9%임상시험 1상태 ACTIVE
CGTBiologicstaleSecond Affiliated Hospital of G…Phase 1

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

EGFR/ B7H3-positive Advanced Lung Cancer; EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING